+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment for psoriasis



Treatment for psoriasis



Vie Medicale 37(Spec No): 115-116




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050832670

Download citation: RISBibTeXText

PMID: 13392493


Related references

Change in induration of target plaques in the first 4-6 weeks of systemic treatment is predictive of the final response to treatment of psoriasis A comparison of the PASI and National Psoriasis Foundation Psoriasis Score. Journal of Investigative Dermatology 119(1): 237, 2002

The article deals with modern aspects of ethiology and pathogenesis of psoriasis and data about treatment of psoriasis vulgaris with immunomodulator Galavitum. It demonstrates Galavitum to be a drug for pathogenetic treatment of psoriasis, acting upon both immune and nervous systems. Vestnik Dermatologii i Venerologii (6): 36-39, 2005

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. Journal of the European Academy of Dermatology and Venereology 29(6): 1148-1155, 2016

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). Journal of Dermatology 44(4): 355-362, 2016

Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Dermato-Venereologica 78(6): 466-467, 1998

Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey. American Journal of Clinical Dermatology 9(2): 111-117, 2008

Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. British Journal of Dermatology 156(Suppl. 2): 7-11, 2007

Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE. British Journal of Dermatology 171(5): 1091-1098, 2015

Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatology 149(10): 1180-1185, 2013

Treatment of psoriasis. New possibility of psoriasis treatment using long-wave UV light and a photosensitizer. Fortschritte der Medizin 93(30): 1484-1487, 1975

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 58(5): 826-850, 2008

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology 75(1): 99-105, 2017

Evaluation of potent phytomedicine for treatment of psoriasis using UV radiation induced psoriasis in rats. Biomedicine and PharmacoTherapy 84: 1156-1162, 2016

Photochemotherapy of psoriasis. A review of mechanism and report of successful, treatment in pustular psoriasis. Journal of the Medical Association of Thailand 60(10): 510-515, 1977

Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 60(6): 962-971, 2009